Abstract
Lung carcinoma (LC) is rare cancer in most parts of the world but is common cancer in southern Asia. Local recurrent disease and distant metastasis of LC are still mysterious challenges. This investigation was to effectively fabricate and evaluate the therapeutic efficiency of Gemcitabine (GEM) and Losmapimod (LOS) encapsulated into polyethylene glycol (PEG)-polylactic-co-glycolic acid (PLGA)-NPs (GEM/LOS@NPs), which exhibited inhibition of in vitro lung cells proliferation. GEM/LOS@NPs with a diameter of ∼100 nm have been constructed employing an enhanced double-emulsion (W/O/W) method. The GEM/LOS@NPs’ particle size was studied through transmission electron microscopic (TEM) techniques and dynamic light scattering (DLS) measurement. After successfully fabricating GEM/LOS@NPs, the anticancer ability of A549 and H460 lung cancer cells was investigated. Biochemical assays such as AO/EB (acridine bromide/orange ethidium) and nuclear staining investigated the cancer cell’s morphology and death. The cell death of the cancer cells was synergically examined by ROS analysis. Overall, these results suggest that highly toxic drugs can be rationally transformed into self-deliverable and pharmacologically efficient monotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
